View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 9, 2020updated 12 Jul 2022 11:56am

OncoImmune gets approval to trial CD24Fc for Covid-19 in US

The US Food and Drug Administration (FDA) has granted approval for OncoImmune to conduct a Phase III clinical trial of CD24Fc to treat patients hospitalised with Covid-19.

The US Food and Drug Administration (FDA) has granted approval for OncoImmune to conduct a Phase III clinical trial of CD24Fc to treat patients hospitalised with Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

CD24Fc is designed to modulate host inflammatory response to tissue injuries which is believed to be involved in autoimmune disease, cancer, graft-versus-host disease (GvHD) and metabolic syndromes.

The novel coronavirus, SARS-CoV-2, leads to clinical symptoms by killing the lung cells. It also causes inflammation that worsens clinical symptoms.

OncoImmune co-founder and CEO Dr Yang Liu said: “CD24Fc is a first-in-class biologic that fortifies an innate immune checkpoint against excessive inflammation caused by tissue-injuries.

“We are very excited to launch a global effort to test the clinical efficacy of CD24Fc in speeding up recovery of hospitalised Covid-19 patients.”

In the new double blind, randomised, multi-centre Phase III trial, CD24Fc’s safety and efficacy will be assessed in around 230 patients exhibiting severe clinical symptoms.

Participants will receive a single 480mg IV infusion of the drug candidate or placebo. Named SAC-COVID, the trial involves a follow-up of 14-days to monitor safety and efficacy in clinical improvement.

The study involves two interim analyses for safety and therapeutic activity, and for therapeutic efficacy, respectively.

CD24Fc will be given in combination with the ‘best available’ treatment, said the company. Patients who are on other experimental therapies can also enrol in the trial.

OncoImmune co-founder and chief medical officer Dr Pan Zheng said: “In addition to anti-viral therapy, a comprehensive strategy in treating Covid-19 patients should include a non-antiviral approach targeting the tissue injury-induced inflammation.”

Previously, the drug candidate was assessed in a Phase IIa trial for prophylaxis of acute GvHD in leukaemia patients receiving hematopoietic stem cell transplantation (HSCT).

Data showed a significant improvement in 180 Day Grade III-IV acute GVHD Free survival.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena